泾阳县学校专业升学率鹤壁中学补习学校专业哪里好,阎良区封闭冲刺正规怎么办,泾阳县新高一高中复读哪家好,鹤壁高考复读哪里有升学率,青岛高一学校专业多少钱,泾阳县高一高中提分快,鄠邑区中考补习靠谱的专业

JERUSALEM, Oct. 24 (Xinhua) -- A recent study carried out by Israeli researchers showed that the experience of motherhood is caused by alterations in the brain functions that help mothers locate and communicate with their offspring, especially if they are in distress.Researchers at the Hebrew University of Jerusalem said the results provide insight into how neural changes in response to odors and sounds help maternal behaviors develop in mothers."We know that distinct brain changes are linked with motherhood, " Dr. Adi Mizrahi, who conducted the research, said, "but the impact of these changes on sensory processing and the emergence of maternal behaviors are largely unknown."Mizrahi and his colleagues examined whether the primary auditory cortex -- a region in the brain that is involved in the recognition of sounds -- might serve to process the responses to their offspring's specific smell and voice.The research proved that the olfactory and auditory senses of female mice with their pups were triggered immediately after they gave birth, with especially strong responses to cries of distress."These processes help to explain how changes in the cortex in the brain facilitate efficient detection of pups," Mizrahi said.

BEIJING, Oct. 13 (Xinhuanet) -- Tyrannosaurus rex dinosaur, the giant prehistoric predator, was even bigger and heavier than it was estimated previously, a new study found.The finding was contained in a study published Wednesday in the scientific journal PLoS ONE.Using three-dimension scanning and computer modeling, researchers analyzed five skeleton fossils of T. rex dinosaur, including "Sue", the largest and most complete T. rex specimen ever found.The analysis tipped the scale of "Sue" at 9 ton, some 30 percent more than it was expected."At their fastest, in their teenage years, they were putting on 11 pounds or 5 kilograms a day," said John Hutchinson of the Royal Veterinary College in London, who co-led the study.The larger body mass indicated the better agility and the stronger lower-leg muscles of the ancient monster, said the researcher."Sue" could have a top speed of about 10-25 miles per hour when it ran on the Great Plains of North America 67 million years ago, Hutchinson suggested.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

BEIJING, Nov. 27 (Xinhua) -- China's industrial enterprises saw their profits increase 25.3 percent year-on-year in the first ten months of 2011, slowing down from the year's previously recorded figures, official data showed Sunday.Growth in the January-October period was 1.7 percentage points lower from that of the first three quarters, the National Bureau of Statistics (NBS) said in a statement.It marked a gradual downshift from the 34.3-percent year-on-year growth seen during the January-February period and the 28.7-percent growth seen during the first half of the year.Profits realized in the first ten months amounted to 4.12 trillion yuan (650 billion U.S. dollars), the NBS said.The NBS compiled the figures using data collected from a pool of industrial businesses with at least 20 million yuan in annual sales revenues each.In October alone, industrial profits expanded 12.5 percent year-on-year to 438.3 billion yuan, the NBS said.Among 39 industries surveyed, 36 sectors reported profit growth in the first ten months. The oil refining, coking and nuclear-fuel processing sector saw profit plunge 89.8 percent year-on-year.Private businesses posted the fastest profit growth, with a year-on-year rise of 44.3 percent, followed by collectively owned enterprises of 33 percent, equity-holding companies of 30.3 percent, state-owned enterprises of 16.6 percent and overseas-funded firms of 11.6 percent.China's industrial production growth rate will moderate due to economic turmoil in Europe and the United States and weakening domestic demand brought about by a tightened monetary policy, Huang Libin, an official with the Ministry of Industry and Information Technology, said last week.China saw its economic growth slow to 9.1 percent in the third quarter of this year from 9.5 percent in the second quarter and 9.7 percent in the first quarter.